Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827875 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy
A Phase 1 study, sponsored by AiViva BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04827875: Completed Phase 1 study, sponsored by AiViva BioPharma.
NCT04827875 is a Phase 1 study that has completed, run by AiViva BioPharma. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04827875, a Phase 1 study, has completed, sponsored by AiViva BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.
Primary Outcome
Incidence of adverse events
Interventions
- DRUG AIV001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-06-23 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 1 |
What the finished NCT04827875 record still lists
NCT04827875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which AIV001 is the first listed.
NCT04827875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04827875 about?
NCT04827875 is a clinical study titled "Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy". To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.
What is the current status of trial NCT04827875?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-06-23. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT04827875?
The interventions under investigation include: AIV001 (DRUG).
Who is sponsoring clinical trial NCT04827875?
This trial is sponsored by AiViva BioPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04827875's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI